Three types of psychotic-like experiences in youth at clinical high risk for psychosis.

Clinical high risk (CHR) Confirmatory factor analysis (CFA) Dimensional Longitudinal Psychosis risk Psychotic-like experiences (PLEs)

Journal

European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 28 01 2020
accepted: 15 05 2020
pubmed: 28 5 2020
medline: 15 12 2021
entrez: 28 5 2020
Statut: ppublish

Résumé

 A fully dimensional model of psychosis implies that psychotic-like experiences (PLEs) connect the entire psychosis spectrum. Three types of self-reported PLEs-persecutory ideation, bizarre experiences, and perceptual abnormalities-are commonly found in the general population. This study assessed the construct, predictive, and incremental validity of self-reported PLEs in youth at clinical high risk for psychotic disorders (CHR).  Self-report data on PLEs (community assessment of psychic experiences; CAPE) were collected from 105 CHR youth (m  Self-reported PLEs were best represented by the same three factors found in the general population: persecutory ideation, bizarre experiences, and perceptual abnormalities. Cross-sectionally, PLEs-particularly persecutory ideation-correlated with interview-rated attenuated psychotic symptoms and self-reported psychosis proneness, depression, and anxiety. Longitudinally, baseline PLEs trended toward predicting 12-month change in positive attenuated psychotic symptoms (r = .29, p  Three types of PLEs were valid in this CHR sample. Self-reported PLEs may be used not only to screen individuals for inclusion in the CHR classification, but also to characterize individuals within this population. Self-reported PLEs may help to forecast which CHR individuals will progress toward psychotic illness.

Sections du résumé

BACKGROUND BACKGROUND
 A fully dimensional model of psychosis implies that psychotic-like experiences (PLEs) connect the entire psychosis spectrum. Three types of self-reported PLEs-persecutory ideation, bizarre experiences, and perceptual abnormalities-are commonly found in the general population. This study assessed the construct, predictive, and incremental validity of self-reported PLEs in youth at clinical high risk for psychotic disorders (CHR).
METHODS METHODS
 Self-report data on PLEs (community assessment of psychic experiences; CAPE) were collected from 105 CHR youth (m
RESULTS RESULTS
 Self-reported PLEs were best represented by the same three factors found in the general population: persecutory ideation, bizarre experiences, and perceptual abnormalities. Cross-sectionally, PLEs-particularly persecutory ideation-correlated with interview-rated attenuated psychotic symptoms and self-reported psychosis proneness, depression, and anxiety. Longitudinally, baseline PLEs trended toward predicting 12-month change in positive attenuated psychotic symptoms (r = .29, p
CONCLUSIONS CONCLUSIONS
 Three types of PLEs were valid in this CHR sample. Self-reported PLEs may be used not only to screen individuals for inclusion in the CHR classification, but also to characterize individuals within this population. Self-reported PLEs may help to forecast which CHR individuals will progress toward psychotic illness.

Identifiants

pubmed: 32458109
doi: 10.1007/s00406-020-01143-w
pii: 10.1007/s00406-020-01143-w
pmc: PMC7688559
mid: NIHMS1597924
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

733-744

Subventions

Organisme : CIHR
ID : DFS-152268
Pays : Canada
Organisme : NIH HHS
ID : R01MH112545-01
Pays : United States
Organisme : NIH HHS
ID : R01MH094650
Pays : United States
Organisme : NIH HHS
ID : R01MH116039-01A1
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH112545
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH116039
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH094650
Pays : United States
Organisme : CIHR
ID : DFS-152268
Pays : Canada
Organisme : NIH HHS
ID : R01MH112545-01
Pays : United States
Organisme : NIH HHS
ID : R01MH116039-01A1
Pays : United States
Organisme : NIH HHS
ID : R01MH094650
Pays : United States

Références

Psychol Med. 2019 Jul;49(10):1589-1599
pubmed: 31088578
Schizophr Res. 2015 Jul;165(2-3):236-42
pubmed: 25935814
Adv Health Sci Educ Theory Pract. 2010 Dec;15(5):625-32
pubmed: 20146096
Eur Psychiatry. 2011 Sep;26(6):396-401
pubmed: 21334860
Psychiatry Res. 2016 Jan 30;235:197-9
pubmed: 26738980
Curr Behav Neurosci Rep. 2015 May 1;2(2):80-89
pubmed: 26052479
JAMA Psychiatry. 2013 Jan;70(1):107-20
pubmed: 23165428
Psychiatry Res. 2015 Aug 30;228(3):894-8
pubmed: 26050011
J Abnorm Psychol. 1994 May;103(2):171-83
pubmed: 8040487
Schizophr Res. 2017 Nov;189:69-74
pubmed: 28254243
Early Interv Psychiatry. 2012 Aug;6(3):300-8
pubmed: 22029711
Psychiatr Q. 1999 Winter;70(4):273-87
pubmed: 10587984
Psychol Methods. 2012 Sep;17(3):399-417
pubmed: 22563845
Early Interv Psychiatry. 2015 Oct;9(5):345-56
pubmed: 25345316
Schizophr Res. 2011 Jun;129(1):42-6
pubmed: 21511440
Arch Gen Psychiatry. 2000 Nov;57(11):1053-8
pubmed: 11074871
Acta Psychiatr Scand. 2003 May;107(5):369-77
pubmed: 12752033
Schizophr Bull. 2006 Apr;32(2):352-9
pubmed: 16254060
Psychol Med. 2009 Feb;39(2):179-95
pubmed: 18606047
Schizophr Res. 2007 Mar;91(1-3):246-53
pubmed: 17239566
Schizophr Bull. 2014 Jan;40(1):120-31
pubmed: 23180756
Dev Psychopathol. 2019 Feb;31(1):379-392
pubmed: 29506584
Schizophr Res. 2000 Sep 29;45(1-2):11-20
pubmed: 10978868
J Consult Clin Psychol. 1988 Dec;56(6):893-7
pubmed: 3204199
Aust N Z J Psychiatry. 2009 Feb;43(2):118-28
pubmed: 19153919
Early Interv Psychiatry. 2008 Aug;2(3):147-53
pubmed: 21352147
Psychiatry Res. 2012 May 30;197(3):353-5
pubmed: 22364932
Schizophr Bull. 2011 Jul;37(4):850-60
pubmed: 20044595
Schizophr Bull. 2016 Jan;42(1):34-44
pubmed: 26150674
JAMA Psychiatry. 2016 Feb;73(2):113-20
pubmed: 26719911
Psychol Med. 2002 Feb;32(2):347-58
pubmed: 11866327
Arch Gen Psychiatry. 2012 Mar;69(3):220-9
pubmed: 22393215
Schizophr Res. 2012 Nov;141(2-3):210-4
pubmed: 22986044
Clin Psychol Rev. 2001 Nov;21(8):1125-41
pubmed: 11702510
Psychol Med. 2009 Apr;39(4):625-34
pubmed: 18606046
Acta Psychiatr Scand. 2004 Oct;110(4):264-72
pubmed: 15352927
Schizophr Res. 2010 Jun;119(1-3):258-65
pubmed: 20347272
Neurosci Biobehav Rev. 2013 Mar;37(3):317-27
pubmed: 23313650
Schizophr Res. 2006 May;84(1):57-66
pubmed: 16630707
Schizophr Res. 2012 Dec;142(1-3):77-82
pubmed: 23043872
Early Interv Psychiatry. 2017 Oct;11(5):411-417
pubmed: 25962504
Schizophr Res. 2013 Sep;149(1-3):104-7
pubmed: 23830544
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683

Auteurs

Henry R Cowan (HR)

Department of Psychology, Northwestern University, Swift Hall, 2029 Sheridan Rd., Evanston, IL, 60208, USA. hrcowan@u.northwestern.edu.

Vijay A Mittal (VA)

Psychology, Psychiatry, Medical Social Sciences, Institute for Policy Research, Northwestern University, Evanston, IL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH